» Articles » PMID: 38473911

Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Mar 13
PMID 38473911
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial dysfunction, a feature of heart failure, leads to a progressive decline in bioenergetic reserve capacity, consisting in a shift of energy production from mitochondrial fatty acid oxidation to glycolytic pathways. This adaptive process of cardiomyocytes does not represent an effective strategy to increase the energy supply and to restore the energy homeostasis in heart failure, thus contributing to a vicious circle and to disease progression. The increased oxidative stress causes cardiomyocyte apoptosis, dysregulation of calcium homeostasis, damage of proteins and lipids, leakage of mitochondrial DNA, and inflammatory responses, finally stimulating different signaling pathways which lead to cardiac remodeling and failure. Furthermore, the parallel neurohormonal dysregulation with angiotensin II, endothelin-1, and sympatho-adrenergic overactivation, which occurs in heart failure, stimulates ventricular cardiomyocyte hypertrophy and aggravates the cellular damage. In this review, we will discuss the pathophysiological mechanisms related to mitochondrial dysfunction, which are mainly dependent on increased oxidative stress and perturbation of the dynamics of membrane potential and are associated with heart failure development and progression. We will also provide an overview of the potential implication of mitochondria as an attractive therapeutic target in the management and recovery process in heart failure.

Citing Articles

GRK2 and Mitochondrial Dynamics in Cardiovascular Health and Disease.

Gatto C, Rusciano M, Visco V, Ciccarelli M Int J Mol Sci. 2025; 26(5).

PMID: 40076919 PMC: 11900936. DOI: 10.3390/ijms26052299.


A Novel Disulfidptosis-Related Diagnostic Gene Signature and Differential Expression Validation in Ischaemic Cardiomyopathy.

Tan X, Xu S, Zeng Y, Yu F, Qin Z, Zhang G J Cell Mol Med. 2025; 29(5):e70475.

PMID: 40070032 PMC: 11897062. DOI: 10.1111/jcmm.70475.


Metabolic reprogramming in cancer and senescence.

Zhang Y, Tang J, Jiang C, Yi H, Guang S, Yin G MedComm (2020). 2025; 6(3):e70055.

PMID: 40046406 PMC: 11879902. DOI: 10.1002/mco2.70055.


Regenerative therapies for myocardial infarction: exploring the critical role of energy metabolism in achieving cardiac repair.

Ren J, Chen X, Wang T, Liu C, Wang K Front Cardiovasc Med. 2025; 12:1533105.

PMID: 39991634 PMC: 11842438. DOI: 10.3389/fcvm.2025.1533105.


Mitochondrial Dysfunction in Cardiac Disease: The Fort Fell.

Paraskevaidis I, Kourek C, Farmakis D, Tsougos E Biomolecules. 2025; 14(12.

PMID: 39766241 PMC: 11673776. DOI: 10.3390/biom14121534.


References
1.
Wilson A, Gill E, Abudalo R, Edgar K, Watson C, Grieve D . Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. Heart. 2017; 104(4):293-299. DOI: 10.1136/heartjnl-2017-311448. View

2.
Bedi Jr K, Snyder N, Brandimarto J, Aziz M, Mesaros C, Worth A . Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016; 133(8):706-16. PMC: 4779339. DOI: 10.1161/CIRCULATIONAHA.115.017545. View

3.
Zhou B, Tian R . Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018; 128(9):3716-3726. PMC: 6118589. DOI: 10.1172/JCI120849. View

4.
Morciano G, Patergnani S, Bonora M, Pedriali G, Tarocco A, Bouhamida E . Mitophagy in Cardiovascular Diseases. J Clin Med. 2020; 9(3). PMC: 7141512. DOI: 10.3390/jcm9030892. View

5.
Kho C, Lee A, Hajjar R . Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol. 2012; 9(12):717-33. PMC: 3651893. DOI: 10.1038/nrcardio.2012.145. View